BIOMAT Database Logo BIOMAT Database Logo

Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996

C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Dipartimento di Farmacologia, Chemioterapia e Tossicologia medica, Istituto di Chirurgia Sperimentale e dei Trapianti, Milan, Italy.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D007421 Intestine, Small The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM. Small Intestine,Intestines, Small,Small Intestines
D007959 Lymphocyte Culture Test, Mixed Measure of histocompatibility at the HL-A locus. Peripheral blood lymphocytes from two individuals are mixed together in tissue culture for several days. Lymphocytes from incompatible individuals will stimulate each other to proliferate significantly (measured by tritiated thymidine uptake) whereas those from compatible individuals will not. In the one-way MLC test, the lymphocytes from one of the individuals are inactivated (usually by treatment with MITOMYCIN or radiation) thereby allowing only the untreated remaining population of cells to proliferate in response to foreign histocompatibility antigens. Leukocyte Culture Test, Mixed,Mixed Lymphocyte Culture Test,Mixed Lymphocyte Reaction,Mixed Leukocyte Culture Test,Mixed Leukocyte Reaction,Leukocyte Reaction, Mixed,Leukocyte Reactions, Mixed,Lymphocyte Reaction, Mixed,Lymphocyte Reactions, Mixed,Mixed Leukocyte Reactions,Mixed Lymphocyte Reactions
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft
D006650 Histocompatibility Testing Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (King, Dictionary of Genetics, 4th ed) Crossmatching, Tissue,HLA Typing,Tissue Typing,Crossmatchings, Tissue,HLA Typings,Histocompatibility Testings,Testing, Histocompatibility,Testings, Histocompatibility,Tissue Crossmatching,Tissue Crossmatchings,Tissue Typings,Typing, HLA,Typing, Tissue,Typings, HLA,Typings, Tissue
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy.
February 1990, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Canine total orthotopic small bowel transplantation under FK 506.
December 1991, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Total orthotopic small bowel transplantation in swine under FK 506.
June 1994, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Effect of FK 506 on orthotopic small bowel transplantation in rats.
June 1992, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Rejection and survival after total orthotopic liver-small bowel allotransplantation in pigs immunosuppressed with FK 506.
October 1996, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation.
December 1990, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
A potent immunosuppressive effect of FK 506 in orthotopic liver transplantation in primates.
February 1990, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
FK 506 and cyclosporine: effect on D-xylose absorption in pigs with orthotopic liver-small bowel allotransplants.
October 1996, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Clinical small bowel or small bowel plus liver transplantation under FK 506.
December 1991, Transplantation proceedings,
C Perego, and O Marelli, and G Rossi, and S Gatti, and P Reggiani, and R Orsenigo, and D Galmarini, and P Franco
Orthotopic liver transplantation in dogs receiving FK-506.
October 1987, Transplantation proceedings,
Copied contents to your clipboard!